Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations.

Xochelli A, Bikos V, Polychronidou E, Galigalidou C, Agathangelidis A, Charlotte F, Moschonas P, Davis Z, Colombo M, Roumelioti M, Sutton LA, Groenen P, van den Brand M, Boudjoghra M, Algara P, Traverse-Glehen A, Ferrer A, Stalika E, Karypidou M, Kanellis G, Kalpadakis C, Mollejo M, Pangalis G, Vlamos P, Amini RM, Pospisilova S, Gonzalez D, Ponzoni M, Anagnostopoulos A, Giudicelli V, Lefranc MP, Espinet B, Panagiotidis P, Piris MA, Du MQ, Rosenquist R, Papadaki T, Belessi C, Ferrarini M, Oscier D, Tzovaras D, Ghia P, Davi F, Hadzidimitriou A, Stamatopoulos K.

J Pathol. 2018 Nov 28. doi: 10.1002/path.5209. [Epub ahead of print]

PMID:
30484876
2.

Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.

Papakonstantinou N, Ntoufa S, Tsagiopoulou M, Moysiadis T, Bhoi S, Malousi A, Psomopoulos F, Mansouri L, Laidou S, Papazoglou D, Gounari M, Pasentsis K, Plevova K, Kuci-Emruli V, Duran-Ferrer M, Davis Z, Ek S, Rossi D, Gaidano G, Ritgen M, Oscier D, Stavroyianni N, Pospisilova S, Davi F, Ghia P, Hadzidimitriou A, Belessi C, Martin-Subero JI, Pott C, Rosenquist R, Stamatopoulos K.

Int J Cancer. 2018 Nov 16. doi: 10.1002/ijc.31999. [Epub ahead of print]

PMID:
30447004
3.

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, Schuh A, Stilgenbauer S.

Haematologica. 2018 Nov 15. pii: haematol.2018.187583. doi: 10.3324/haematol.2018.187583. [Epub ahead of print]

4.

Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.

Zaprazna K, Reblova K, Svobodova V, Radova L, Bystry V, Baloun J, Durechova K, Tom N, Loja T, Buresova M, Stranska K, Oltova A, Doubek M, Atchison ML, Trbusek M, Malcikova J, Pospisilova S.

Ann Hematol. 2018 Oct 27. doi: 10.1007/s00277-018-3520-5. [Epub ahead of print]

PMID:
30368590
5.

A novel germline mutation in GP1BA gene N-terminal domain in monoallelic Bernard-Soulier syndrome.

Trizuljak J, Kozubík KS, Radová L, Pešová M, Pál K, Réblová K, Stehlíková O, Smejkal P, Zavřelová J, Pacejka M, Mayer J, Pospíšilová Š, Doubek M.

Platelets. 2018 Dec;29(8):827-833. doi: 10.1080/09537104.2018.1529300. Epub 2018 Oct 17.

PMID:
30332551
6.

Dibasic Derivatives of Phenylcarbamic Acid against Mycobacterial Strains: Old Drugs and New Tricks?

Malík I, Csöllei J, Solovič I, Pospíšilová Š, Michnová H, Jampílek J, Čížek A, Kapustíková I, Čurillová J, Pecháčová M, Stolaříková J, Pecher D, Oravec M.

Molecules. 2018 Sep 28;23(10). pii: E2493. doi: 10.3390/molecules23102493.

7.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.

Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Sep 27. pii: haematol.2018.195032. doi: 10.3324/haematol.2018.195032. [Epub ahead of print]

8.

CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.

Hernández-Sánchez M, Kotaskova J, Rodríguez AE, Radova L, Tamborero D, Abáigar M, Plevova K, Benito R, Tom N, Quijada-Álamo M, Bikos V, Martín AÁ, Pal K, García de Coca A, Doubek M, López-Bigas N, Hernández-Rivas JM, Pospisilova S.

Leukemia. 2018 Sep 12. doi: 10.1038/s41375-018-0255-1. [Epub ahead of print] No abstract available.

PMID:
30209402
9.

MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.

Cerna K, Oppelt J, Chochola V, Musilova K, Seda V, Pavlasova G, Radova L, Arigoni M, Calogero RA, Benes V, Trbusek M, Brychtova Y, Doubek M, Mayer J, Pospisilova S, Mraz M.

Leukemia. 2018 Aug 15. doi: 10.1038/s41375-018-0230-x. [Epub ahead of print]

PMID:
30111844
10.

Synthesis and Spectrum of Biological Activities of Novel N-arylcinnamamides.

Pospisilova S, Kos J, Michnova H, Kapustikova I, Strharsky T, Oravec M, Moricz AM, Bakonyi J, Kauerova T, Kollar P, Cizek A, Jampilek J.

Int J Mol Sci. 2018 Aug 7;19(8). pii: E2318. doi: 10.3390/ijms19082318.

11.

C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.

Staňo Kozubík K, Radová L, Pešová M, Réblová K, Trizuljak J, Plevová K, Fiamoli V, Gumulec J, Urbánková H, Szotkowski T, Mayer J, Pospíšilová Š, Doubek M.

Int J Hematol. 2018 Dec;108(6):652-657. doi: 10.1007/s12185-018-2514-3. Epub 2018 Aug 6.

PMID:
30083851
12.

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.

Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Seda V, Fojtova M, Fajkus J, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M.

Leukemia. 2018 Sep;32(9):2028-2031. doi: 10.1038/s41375-018-0211-0. Epub 2018 Jul 20. No abstract available.

PMID:
30030508
13.

ToTem: a tool for variant calling pipeline optimization.

Tom N, Tom O, Malcikova J, Pavlova S, Kubesova B, Rausch T, Kolarik M, Benes V, Bystry V, Pospisilova S.

BMC Bioinformatics. 2018 Jun 26;19(1):243. doi: 10.1186/s12859-018-2227-x.

14.

In vitro activity of salicylamide derivatives against vancomycin-resistant enterococci.

Pospisilova S, Michnova H, Kauerova T, Pauk K, Kollar P, Vinsova J, Imramovsky A, Cizek A, Jampilek J.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2184-2188. doi: 10.1016/j.bmcl.2018.05.011. Epub 2018 May 14.

PMID:
29773506
15.

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Lobello C, Bikos V, Janikova A, Pospisilova S.

Cancers (Basel). 2018 Mar 5;10(3). pii: E64. doi: 10.3390/cancers10030064. Review.

16.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network.

Leukemia. 2018 May;32(5):1070-1080. doi: 10.1038/s41375-017-0007-7. Epub 2018 Feb 2. Review.

17.

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.

Janovska P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, Skabrahova H, Radaszkiewicz T, Ovesna P, Vondalova Blanarova O, Nemcova T, Hoferova Z, Vasickova K, Smyckova L, Egle A, Pavlova S, Poppova L, Plevova K, Pospisilova S, Bryja V.

Blood. 2018 Mar 15;131(11):1206-1218. doi: 10.1182/blood-2017-05-786947. Epub 2018 Jan 9.

PMID:
29317454
18.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Apr;103(4):e158-e161. doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21. No abstract available.

19.

Primaquine hybrids as promising antimycobacterial and antimalarial agents.

Pavić K, Perković I, Pospíšilová Š, Machado M, Fontinha D, Prudêncio M, Jampilek J, Coffey A, Endersen L, Rimac H, Zorc B.

Eur J Med Chem. 2018 Jan 1;143:769-779. doi: 10.1016/j.ejmech.2017.11.083. Epub 2017 Dec 2.

PMID:
29220797
20.

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.

Plešingerová H, Janovská P, Mishra A, Smyčková L, Poppová L, Libra A, Plevová K, Ovesná P, Radová L, Doubek M, Pavlová Š, Pospíšilová Š, Bryja V.

Haematologica. 2018 Feb;103(2):313-324. doi: 10.3324/haematol.2017.178699. Epub 2017 Nov 9.

21.

Transcription factor YY1 can control AID-mediated mutagenesis in mice.

Zaprazna K, Basu A, Tom N, Jha V, Hodawadekar S, Radova L, Malcikova J, Tichy B, Pospisilova S, Atchison ML.

Eur J Immunol. 2018 Feb;48(2):273-282. doi: 10.1002/eji.201747065. Epub 2017 Nov 14.

PMID:
29080214
22.

Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.

Rodríguez-Vicente AE, Bikos V, Hernández-Sánchez M, Malcikova J, Hernández-Rivas JM, Pospisilova S.

Oncotarget. 2017 Jul 24;8(41):71234-71248. doi: 10.18632/oncotarget.19525. eCollection 2017 Sep 19. Review.

23.

GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data.

Pal K, Bystry V, Reigl T, Demko M, Krejci A, Touloumenidou T, Stalika E, Tichy B, Ghia P, Stamatopoulos K, Pospisilova S, Malcikova J, Darzentas N.

Bioinformatics. 2017 Dec 1;33(23):3802-3804. doi: 10.1093/bioinformatics/btx423.

PMID:
29036643
24.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17.

25.

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.

Brazdilova K, Plevova K, Skuhrova Francova H, Kockova H, Borsky M, Bikos V, Malcikova J, Oltova A, Kotaskova J, Tichy B, Brychtova Y, Mayer J, Doubek M, Pospisilova S.

Leukemia. 2018 Jan;32(1):234-236. doi: 10.1038/leu.2017.274. Epub 2017 Aug 29. No abstract available.

26.

Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia.

Vavrova E, Kantorova B, Vonkova B, Kabathova J, Skuhrova-Francova H, Diviskova E, Letocha O, Kotaskova J, Brychtova Y, Doubek M, Mayer J, Pospisilova S.

Leuk Res. 2017 Sep;60:145-150. doi: 10.1016/j.leukres.2017.08.001. Epub 2017 Aug 7.

PMID:
28837890
27.

MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNome profiling of human hippocampus.

Bencurova P, Baloun J, Musilova K, Radova L, Tichy B, Pail M, Zeman M, Brichtova E, Hermanova M, Pospisilova S, Mraz M, Brazdil M.

Epilepsia. 2017 Oct;58(10):1782-1793. doi: 10.1111/epi.13870. Epub 2017 Aug 16.

28.

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M.

Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.

29.

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).

Haematologica. 2017 Jun;102(6):968-971. doi: 10.3324/haematol.2017.165605. No abstract available.

30.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. doi: 10.1158/1078-0432.CCR-16-3100. Epub 2017 May 23.

31.

[Use of Porous Hydrogel as a 3D Scaffold for the Growth of Leukemic B Lymphocytes].

Studená R, Horák D, Baloun J, Plichta Z, Pospíšilová Š.

Klin Onkol. 2017 Spring;30(Supplementum1):184-186. Czech.

PMID:
28471202
32.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

33.

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E.

Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13.

34.

Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.

Vardi A, Vlachonikola E, Karypidou M, Stalika E, Bikos V, Gemenetzi K, Maramis C, Siorenta A, Anagnostopoulos A, Pospisilova S, Maglaveras N, Chouvarda I, Stamatopoulos K, Hadzidimitriou A.

Leukemia. 2017 Jul;31(7):1555-1561. doi: 10.1038/leu.2016.362. Epub 2016 Nov 25.

PMID:
27904140
35.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F.

Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28.

PMID:
27890934
36.

Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia.

Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, Gnan C, Pippucci T, Bozzi V, Faleschini M, Barozzi S, Doubek M, Di Buduo CA, Kozubik KS, Radova L, Loffredo G, Pospisilova S, Alfano C, Seri M, Balduini CL, Pecci A, Savoia A.

Haematologica. 2016 Nov;101(11):1333-1342. Epub 2016 Jun 30.

37.

Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs.

Pazourkova E, Pospisilova S, Svobodova I, Horinek A, Brisuda A, Soukup V, Hrbacek J, Capoun O, Mares J, Hanus T, Babjuk M, Korabecna M.

Adv Exp Med Biol. 2016;924:97-100.

PMID:
27753026
38.

The Structure-Antimicrobial Activity Relationships of a Promising Class of the Compounds Containing the N-Arylpiperazine Scaffold.

Malík I, Csöllei J, Jampílek J, Stanzel L, Zadražilová I, Hošek J, Pospíšilová Š, Čížek A, Coffey A, O'Mahony J.

Molecules. 2016 Sep 26;21(10). pii: E1274.

39.

Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.

Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, Kotaskova J, Kantorova B, Hlozkova M, Figulova J, Brychtova Y, Machalova M, Urik M, Doubek M, Kozubik A, Pospisilova S, Pavlova S, Bryja V.

Br J Haematol. 2016 Dec;175(5):851-859. doi: 10.1111/bjh.14312. Epub 2016 Sep 21.

PMID:
27651098
40.

Synthesis and Antimicrobial Evaluation of 1-[(2-Substituted phenyl)carbamoyl]naphthalen-2-yl Carbamates.

Gonec T, Pospisilova S, Holanova L, Stranik J, Cernikova A, Pudelkova V, Kos J, Oravec M, Kollar P, Cizek A, Jampilek J.

Molecules. 2016 Sep 7;21(9). pii: E1189. doi: 10.3390/molecules21091189.

41.

N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity.

Gonec T, Pospisilova S, Kauerova T, Kos J, Dohanosova J, Oravec M, Kollar P, Coffey A, Liptaj T, Cizek A, Jampilek J.

Molecules. 2016 Aug 16;21(8). pii: E1068. doi: 10.3390/molecules21081068.

42.

High-quality full-length immunoglobulin profiling with unique molecular barcoding.

Turchaninova MA, Davydov A, Britanova OV, Shugay M, Bikos V, Egorov ES, Kirgizova VI, Merzlyak EM, Staroverov DB, Bolotin DA, Mamedov IZ, Izraelson M, Logacheva MD, Kladova O, Plevova K, Pospisilova S, Chudakov DM.

Nat Protoc. 2016 Sep;11(9):1599-616. doi: 10.1038/nprot.2016.093. Epub 2016 Aug 4.

PMID:
27490633
43.

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M.

Blood. 2016 Sep 22;128(12):1609-13. doi: 10.1182/blood-2016-04-709519. Epub 2016 Aug 1.

44.

ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Navrkalova V, Young E, Baliakas P, Radova L, Sutton LA, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Touloumenidou T, Davi F, Langerak AW, Ghia P, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M.

Haematologica. 2016 Sep;101(9):e369-73. doi: 10.3324/haematol.2016.142968. Epub 2016 Jun 16. No abstract available.

45.

Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.

Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, Radova L, Tom N, Trbusek M, Diviskova E, Francova HS, Navrkalova V, Doubek M, Brychtova Y, Mayer J, Pospisilova S.

Br J Haematol. 2017 Sep;178(6):979-982. doi: 10.1111/bjh.14176. Epub 2016 Jul 29. No abstract available.

PMID:
27470445
46.

MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection.

Pospisilova S, Pazourkova E, Horinek A, Brisuda A, Svobodova I, Soukup V, Hrbacek J, Capoun O, Hanus T, Mares J, Korabecna M, Babjuk M.

Neoplasma. 2016;63(5):799-808. doi: 10.4149/neo_2016_518.

PMID:
27468885
47.

Differentially expressed miRNAs in trisomy 21 placentas.

Svobodová I, Korabečná M, Calda P, Břešťák M, Pazourková E, Pospíšilová Š, Krkavcová M, Novotná M, Hořínek A.

Prenat Diagn. 2016 Aug;36(8):775-84. doi: 10.1002/pd.4861. Epub 2016 Jul 18.

PMID:
27323694
48.

Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.

Raskova Kafkova L, Navrkalova V, Jarosova M, Loja T, Chovancova J, Kucerova J, Kriegova E, Prochazka V, Novak Z, Simkova D, Pospisilova S, Divoky V.

Leuk Lymphoma. 2017 Jan;58(1):199-203. Epub 2016 Jun 7. No abstract available.

PMID:
27268868
49.

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfò L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL.

Haematologica. 2016 Aug;101(8):959-67. doi: 10.3324/haematol.2016.141812. Epub 2016 May 19.

50.

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.

Plesingerova H, Librova Z, Plevova K, Libra A, Tichy B, Skuhrova Francova H, Vrbacky F, Smolej L, Mayer J, Bryja V, Doubek M, Pospisilova S.

Leuk Lymphoma. 2017 Jan;58(1):70-79. Epub 2016 May 17.

PMID:
27185377

Supplemental Content

Loading ...
Support Center